Vitalik Buterin floats native DVT staking proposal to boost Ethereum security and decentra

2026-01-21T03:39:53-08:00

Vitalik Buterin's proposal aims to boost network resilience by integrating native DVT technology into Ethereum’s staking protocol. 

Vitalik Buterin floats native DVT staking proposal to boost Ethereum security and decentra2026-01-21T03:39:53-08:00

Amazon CEO Andy Jassy goes wobbly on AI bubble possibility

2026-01-21T03:29:16-08:00

Could one of the most prominent tech company leaders be less-than-enthused about the AI economy? In an interview, Amazon CEO Andy Jassy didn't dismiss the idea that the AI bubble ...

Amazon CEO Andy Jassy goes wobbly on AI bubble possibility2026-01-21T03:29:16-08:00

The Big Five Amazon Best-Selling New Release Cameras Right Now

2026-01-21T03:24:47-08:00

In continuation of our previous Big-5 (but full-frame) piece, we are now on Amazon’s Best-Selling New Releases list, which is one of the most reliable real-world indicators of what creators ...

The Big Five Amazon Best-Selling New Release Cameras Right Now2026-01-21T03:24:47-08:00

Bitcoin stages rebound to nearly $90,000 as traders await Trump’s Davos talks

2026-01-21T03:20:11-08:00

BTC and major altcoins saw early signs of stabilization after macro-driven losses. 

Bitcoin stages rebound to nearly $90,000 as traders await Trump’s Davos talks2026-01-21T03:20:11-08:00

MSTY: Using WNTR To Offset Downside Until Strategy And Bitcoin Recovery

2026-01-21T03:05:38-08:00

MSTY delivers high option income but tracks MSTR/Bitcoin swings. Pair with WNTR (short MSTR) to hedge downside and keep yield. Read the full analysis here. 

MSTY: Using WNTR To Offset Downside Until Strategy And Bitcoin Recovery2026-01-21T03:05:38-08:00

The ARK 21Shares Bitcoin ETF: Buy, Sell, or Hold in 2026?

2026-01-21T03:01:57-08:00

The ARK 21Shares Bitcoin ETF is an easy way for investors to gain exposure to Bitcoin. Given that Cathie Wood and her team at Ark Invest are such big fans ...

The ARK 21Shares Bitcoin ETF: Buy, Sell, or Hold in 2026?2026-01-21T03:01:57-08:00

No Robust Evidence to Support Cannabis Products for Chronic Neuropathic Pain

2026-01-21T02:58:57-08:00

A newly updated review suggests that there is limited evidence to support the use of cannabis-based medications for chronic neuropathic pain. Investigators analyzed 21 clinical trials involving more than 2100 ...

No Robust Evidence to Support Cannabis Products for Chronic Neuropathic Pain2026-01-21T02:58:57-08:00
Go to Top